tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AKBA Stock Latest News

Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Company AnnouncementsAkebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
3d ago
AKBA
Akebia price target lowered to $4 from $6 at Piper Sandler
PremiumThe Fly
Akebia price target lowered to $4 from $6 at Piper Sandler
8d ago
AKBA
Akebia Therapeutics Updates Executive Severance and Leadership Terms
PremiumCompany Announcements
Akebia Therapeutics Updates Executive Severance and Leadership Terms
14d ago
8K
AKBA
Akebia announces corporate updates, 2026 pipeline outlook
PremiumThe Fly
Akebia announces corporate updates, 2026 pipeline outlook
1M ago
AKBA
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
PremiumCompany Announcements
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
1M ago
8K
AKBA
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
PremiumRatingsAkebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
1M ago
AKBA
Akebia announces first patient dosed in Phase 2 trial of praliciguat
Premium
The Fly
Akebia announces first patient dosed in Phase 2 trial of praliciguat
1M ago
AKBA
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
Premium
Ratings
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
2M ago
AKBA
Akebia Therapeutics Acquires Global Rights to ADX-097
PremiumCompany Announcements
Akebia Therapeutics Acquires Global Rights to ADX-097
2M ago
8K
AKBA
Akebia Therapeutics announces establishment of rare kidney disease pipeline
PremiumThe Fly
Akebia Therapeutics announces establishment of rare kidney disease pipeline
2M ago
AKBA
QTTB
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
PremiumThe Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
2M ago
AKBA
QTTB
Q32 Bio sells complement inhibitor ADX-097 to Akebia
PremiumThe Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia
2M ago
AKBA
QTTB
Akebia Therapeutics Amends License Agreement with MEDICE
PremiumCompany AnnouncementsAkebia Therapeutics Amends License Agreement with MEDICE
3M ago
8K
AKBA
Akebia Therapeutics’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Akebia Therapeutics’ Earnings Call: Growth Amid Challenges
3M ago
AKBA
Akebia Therapeutics Reports Strong Q3 2025 Growth
Premium
Company Announcements
Akebia Therapeutics Reports Strong Q3 2025 Growth
3M ago
AKBA
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
PremiumThe Fly
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
3M ago
JD
CNC
Akebia reports Q3 EPS 0c vs (10c) last year
PremiumThe Fly
Akebia reports Q3 EPS 0c vs (10c) last year
3M ago
AKBA
AKBA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
AKBA Upcoming Earnings Report: What to Expect?
3M ago
AKBA
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics
PremiumRatings
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics
4M ago
AKBA
Akebia price target lowered to $6 from $8 at H.C. Wainwright
PremiumThe FlyAkebia price target lowered to $6 from $8 at H.C. Wainwright
4M ago
AKBA
Akebia Therapeutics Halts VALOR Trial for Vadadustat
Premium
Company Announcements
Akebia Therapeutics Halts VALOR Trial for Vadadustat
4M ago
8K
AKBA
Akebia says not in alignment with FDA on path forward for VALOR clinical trial
Premium
The Fly
Akebia says not in alignment with FDA on path forward for VALOR clinical trial
4M ago
AKBA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >